[go: up one dir, main page]

BR0314783A - Pirróis 3,4-dissubstituìdos e seu uso no tratamento de doenças inflamatórias - Google Patents

Pirróis 3,4-dissubstituìdos e seu uso no tratamento de doenças inflamatórias

Info

Publication number
BR0314783A
BR0314783A BR0314783-5A BR0314783A BR0314783A BR 0314783 A BR0314783 A BR 0314783A BR 0314783 A BR0314783 A BR 0314783A BR 0314783 A BR0314783 A BR 0314783A
Authority
BR
Brazil
Prior art keywords
treatment
inflammatory diseases
disubstituted pyrroles
substituted
pharmaceutical compositions
Prior art date
Application number
BR0314783-5A
Other languages
English (en)
Inventor
James L Bullington
Xiaodong Fan
Paul F Jackson
Yue-Mei Zhang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR0314783A publication Critical patent/BR0314783A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)

Abstract

"PIRRóIS 3,4-DISSUBSTITUìDOS E SEU USO NO TRATAMENTO DE DOENçAS INFLAMATóRIAS". Esta invenção fornece 3-(2,5-substituídos)-piridil-4-aril-pirróis substituídos, inusitados, e composições farmacêuticas que compreendem os mesmos, úteis para tratar distúrbios que são melhorados pela redução da produção de TNF-<244> e/ou da atividade de p38 em células apropriadas. Esta invenção fornece também métodos terapêuticos e profiláticos que usam as presentes composições farmacêuticas.
BR0314783-5A 2002-09-27 2003-09-24 Pirróis 3,4-dissubstituìdos e seu uso no tratamento de doenças inflamatórias BR0314783A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41443602P 2002-09-27 2002-09-27
PCT/US2003/030223 WO2004029040A1 (en) 2002-09-27 2003-09-24 3,4-disubstituted pyrroles and their for use in treating inflammatory diseases

Publications (1)

Publication Number Publication Date
BR0314783A true BR0314783A (pt) 2005-07-26

Family

ID=32043390

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314783-5A BR0314783A (pt) 2002-09-27 2003-09-24 Pirróis 3,4-dissubstituìdos e seu uso no tratamento de doenças inflamatórias

Country Status (16)

Country Link
US (1) US20050043331A1 (pt)
EP (1) EP1549635A1 (pt)
JP (1) JP2006511479A (pt)
KR (1) KR20050053694A (pt)
CN (1) CN1701069A (pt)
AR (1) AR041416A1 (pt)
AU (1) AU2003278927A1 (pt)
BR (1) BR0314783A (pt)
CA (1) CA2500221A1 (pt)
MX (1) MXPA05003264A (pt)
NO (1) NO20051967L (pt)
PL (1) PL376056A1 (pt)
RU (1) RU2005108586A (pt)
TW (1) TW200512207A (pt)
WO (1) WO2004029040A1 (pt)
ZA (1) ZA200503383B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4808154B2 (ja) * 2003-03-13 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用な組成物
FR2870237B1 (fr) * 2004-05-14 2008-09-26 Centre Nat Rech Scient Cnrse Derives arylpyrroliques, arylfulraniques et arylthiopheniques a action antitubuline, procede de preparation et utilisation en tant qu'antimitotique
EP1786409A1 (en) * 2004-09-01 2007-05-23 Ethicon, Inc. Wound healing
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
PE20070182A1 (es) 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
WO2007149395A2 (en) * 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
DE102006049452A1 (de) * 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
KR20100095430A (ko) * 2007-11-02 2010-08-30 메틸진 인크. 히스톤 탈아세틸화효소의 저해물질
US9308254B2 (en) * 2010-02-17 2016-04-12 Imperial Innovations Limited Method for treatment of post operative cognitive dysfunction
WO2012121988A2 (en) * 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
CN107011236A (zh) * 2017-05-31 2017-08-04 南京佰泰克生物技术有限公司 一种提高cik细胞对胃癌杀伤力的化合物及其制剂
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP7012152B2 (ja) 2017-10-05 2022-02-10 フルクラム セラピューティクス，インコーポレイテッド Ｆｓｈｄの治療のためにｄｕｘ４および下流遺伝子発現を低減するｐ３８キナーゼ阻害剤
CN109221384A (zh) * 2018-09-21 2019-01-18 五邑大学 一种含吡咯化合物的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275206A (en) * 1979-03-05 1981-06-23 Appleton Papers Inc. Lactone compounds containing an indolizine radical
DE4419246A1 (de) * 1994-06-01 1995-12-07 Merckle Gmbh Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie
JPH11510511A (ja) * 1995-08-10 1999-09-14 メルク エンド カンパニー インコーポレーテッド ２，５−置換アリールピロール、この化合物を含有する組成物及び使用方法
WO1997016442A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
EP1178981B1 (en) * 1999-05-14 2003-06-25 Ortho-Mcneil Pharmaceutical, Inc. Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
DE10004157A1 (de) * 2000-02-01 2001-08-02 Merckle Gmbh Chem Pharm Fabrik 4-Pyridyl-und 2,4-Pyrimidinyl-substituierte Pyrrolderivate und ihre Anwendung in der Pharmazie

Also Published As

Publication number Publication date
JP2006511479A (ja) 2006-04-06
ZA200503383B (en) 2006-07-26
WO2004029040A1 (en) 2004-04-08
KR20050053694A (ko) 2005-06-08
AU2003278927A1 (en) 2004-04-19
AR041416A1 (es) 2005-05-18
EP1549635A1 (en) 2005-07-06
TW200512207A (en) 2005-04-01
PL376056A1 (en) 2005-12-12
NO20051967L (no) 2005-06-21
CN1701069A (zh) 2005-11-23
RU2005108586A (ru) 2005-10-10
US20050043331A1 (en) 2005-02-24
MXPA05003264A (es) 2005-10-18
CA2500221A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
GB0222495D0 (en) Compounds
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EA200300492A1 (ru) 2-, 3-, 4- или 5-замещенные n1-(бензолсульфонил)индолы и их применение в терапии
MY137053A (en) Pyrimidine derivatives and their use as cb2 modulators
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DK1639013T3 (da) Pan-kir2dl-nk-receptor-antistoffer og anvendelse heraf til diagnosticering og terapi
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
BR0314783A (pt) Pirróis 3,4-dissubstituìdos e seu uso no tratamento de doenças inflamatórias
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200611695A (en) Pyrrolopyridine derivatives
DK0832081T3 (da) Bicykliske-aromatiske forbindelser
IL163026A (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
AU2003260436A1 (en) Pyrimidine compounds
ATE402958T1 (de) Antagonisten des ige-rezeptors
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
MXPA05003718A (es) Compuestos x-nitro, sus composiciones farmaceuticas y sus usos.
BR0010560A (pt) 3-piridil-4-arilpirrois substituìdos e métodos terapêuticos e profiláticos relacionados
WO2005011611A3 (en) Bicyclic compounds and compositions as pdf inhibitors

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON (US)

Free format text: TRANSFERIDO DE: JANSSEN PHARMACEUTICA N.V.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A., 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.